他扎罗汀结构式
|
常用名 | 他扎罗汀 | 英文名 | Tazarotene |
---|---|---|---|---|
CAS号 | 118292-40-3 | 分子量 | 351.462 | |
密度 | 1.2±0.1 g/cm3 | 沸点 | 499.8±45.0 °C at 760 mmHg | |
分子式 | C21H21NO2S | 熔点 | 97-98ºC | |
MSDS | 中文版 美版 | 闪点 | 256.1±28.7 °C |
他扎罗汀用途Tazarotene是选择性视黄酸受体 (RAR) 激动剂,用于治疗斑块状银屑病和寻常痤疮。 |
中文名 | 他扎罗汀 |
---|---|
英文名 | tazarotene |
中文别名 | 6-[2-(4,4-二甲基二氢苯并噻喃-6-基)乙炔基]吡啶-3-甲酸乙酯 |
英文别名 | 更多 |
描述 | Tazarotene是选择性视黄酸受体 (RAR) 激动剂,用于治疗斑块状银屑病和寻常痤疮。 |
---|---|
相关类别 | |
体外研究 | 凝胶和乳膏制剂中的他扎罗汀既可用作单一疗法,也可用作辅助疗法。对于牛皮癣,它已经与类固醇,卡泊三烯和光疗法以及痤疮,抗生素联合使用。他扎罗汀已被证明可上调肿瘤抑制因子,他扎罗汀诱导的基因3,该基因在牛皮癣和皮肤癌中过度表达[1]。在人表皮细胞培养物中,他扎罗汀抑制2种标志物蛋白MRP-8(钙粒蛋白A)和SKALP(皮肤衍生的抗白细胞蛋白酶)的基因表达,在银屑病表皮中高度升高[2]。 |
体内研究 | 局部凝胶应用提供了他扎罗汀直接递送到皮肤中。在向健康个体和患有银屑病的患者的皮肤局部施用0.1%他扎罗汀凝胶后10小时,约4至6%的剂量存在于角质层中,2%的剂量分布至活表皮和真皮。他扎罗汀被设计为对其活性代谢物他扎罗汀酸进行快速和完全的代谢。 Tazarotenic acid具有较短的全身停留时间和有限的动物组织分布[3]。当局部应用时,他扎罗汀通过肿瘤促进剂12-O-十四烷基佛波醇13-乙酸酯(TPA)阻断鸟氨酸脱羧酶(ODC)活性的诱导。无毛小鼠的表皮[3]。 |
参考文献 |
密度 | 1.2±0.1 g/cm3 |
---|---|
沸点 | 499.8±45.0 °C at 760 mmHg |
熔点 | 97-98ºC |
分子式 | C21H21NO2S |
分子量 | 351.462 |
闪点 | 256.1±28.7 °C |
精确质量 | 351.129303 |
PSA | 64.49000 |
LogP | 6.22 |
外观性状 | 白色固体 |
蒸汽压 | 0.0±1.3 mmHg at 25°C |
折射率 | 1.625 |
储存条件 | Store at +4°C |
危险品运输编码 | NONH for all modes of transport |
---|---|
海关编码 | 2942000000 |
~61% 他扎罗汀 118292-40-3 |
文献:INDOCO REMEDIES LIMITED Patent: WO2009/116075 A2, 2009 ; Location in patent: Page/Page column 12 ; |
~% 他扎罗汀 118292-40-3 |
文献:WO2006/59345 A2, ; Page/Page column 20-21 ; |
~% 他扎罗汀 118292-40-3 |
文献:US2007/238881 A1, ; Page/Page column 6 ; |
~% 他扎罗汀 118292-40-3 |
文献:US2007/238881 A1, ; Page/Page column 7 ; |
~% 他扎罗汀 118292-40-3 |
文献:US2007/238881 A1, ; Page/Page column 7 ; |
~% 他扎罗汀 118292-40-3 |
文献:Organic Process Research and Development, , vol. 9, # 5 p. 646 - 650 |
~% 他扎罗汀 118292-40-3 |
文献:Organic Process Research and Development, , vol. 9, # 5 p. 646 - 650 |
~% 他扎罗汀 118292-40-3 |
文献:Organic Process Research and Development, , vol. 9, # 5 p. 646 - 650 |
海关编码 | 2934999090 |
---|---|
中文概述 | 2934999090. 其他杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
申报要素 | 品名, 成分含量, 用途 |
Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
A custom tailored model to investigate skin penetration in porcine skin and its comparison with human skin.
Eur. J. Pharm. Biopharm. 95 , 99-109, (2015) Reliable models for the determination of skin penetration and permeation are important for the development of new drugs and formulations. The intention of our study was to develop a skin penetration m... |
|
Tazarotene versus tretinoin or adapalene in the treatment of acne vulgaris.
J. Am. Acad. Dermatol. 43(2 Pt 3) , S51-4, (2000) The efficacy and tolerability of tazarotene 0.1% gel in the treatment of acne vulgaris have been compared with those of tretinoin 0.025% gel and adapalene 0.1% gel in multicenter, double-blind, random... |
|
Retinoic acid receptor signaling preserves tendon stem cell characteristics and prevents spontaneous differentiation in vitrox.
Stem Cell Res. Ther. 7 , 45, (2016) Previous studies have reported that adult mesenchymal stem cells (MSCs) tend to gradually lose their stem cell characteristics in vitro when placed outside their niche environment. They subsequently u... |
3-pyridinecarboxylic acid, 6-[(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-, ethyl ester |
Avage |
Ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinate |
ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate |
6-[(4,4-diméthyl-3,4-dihydro-2H-thiochromén-6-yl)éthynyl]pyridine-3-carboxylate d'éthyle |
6-[(3,4-Dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid ethyl ester |
Ethyl 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate |
Ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinate |
Tazorac |
3-Pyridinecarboxylic acid, 6-[2-(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]-, ethyl ester |
Tazarotene |
Zorac |
Ethyl-6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethinyl]pyridin-3-carboxylat |
ethyl 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate |
MFCD00867628 |